Solid Biosciences Inc (SLDB)


Stock Price Forecast

Feb. 21, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Solid Biosciences Inc chart...

About the Company

Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, its mandate is simple yet comprehensive - work to address the disease at its core by correcting the underlying mutation that causes Duchenne with its lead gene therapy candidate, SGT-001.

Employees

70

Exchange

NASDAQ

Website

solidbio.com

$12M

Total Revenue

70

Employees

$68M

Market Capitalization

-0.85

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SLDB News

Solid Biosciences (SLDB) Gets a Buy from Barclays

19h ago, source:

In a report released yesterday, Gena Wang from Barclays assigned a Buy rating to Solid Biosciences (SLDB – Research Report), with a price ...

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

5d ago, source:

Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million ...

Solid Biosciences Stock Drops 4% Due To Wider Loss In Q4

5d ago, source:

Stock of Solid Biosciences Inc. (SLDB) is moving down over 4 percent on Wednesday morning following the announcement of an increase ...

Solid Biosciences to Participate at Upcoming Investor Conferences

12d ago, source:

CHARLESTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SLDB), a life sciences company developing precision genetic ...

Solid Biosciences Inc SLDB

11d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Solid Biosciences Stock Drops 4% Due To Wider Loss In Q4

5d ago, source: Nasdaq

(RTTNews) - Stock of Solid Biosciences Inc. (SLDB) is moving down over 4 percent on Wednesday morning following the announcement of an increase in loss in the fourth-quarter. The company's loss ...

Solid Biosciences Inc SLDB

18d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Solid Biosciences Inc.: Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

5d ago, source:

Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 ...

Solid Biosciences to Participate at Upcoming Investor Conferences

13d ago, source: ADVFN

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...